ArticleHeliyon2023

Presence of MET exon 14 skipping and fusion as mechanism of osimertinb resistance in a lung adenocarcinoma with an EGFR exon 19 deletion that responds to combination of capmatinib and osimertinb: A case report.

Siqi Xiang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.